News
-
Consort Medical subsidiaries Aesica and Bespak will manufacture Opiant Pharmaceuticals’ OPNT003 nalmefene nasal spray, the companies said. Earlier this year, Opiant announced that it would develop OPNT003 for the treatment of opioid overdose using the… Read more . . .
-
Glenmark Pharmaceuticals announced that it has received marketing approval from German authorities for its generic version of Seretide Accuhaler and said that the product will be marketed in Germany as “Salflutin.” The company acquired development… Read more . . .
-
Roivant Sciences has acquired global rights to Patara Pharma’s PA101 cromolyn sodium inhalation solution for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), the company said. The inhalation solution, which will… Read more . . .
-
United Therapeutics will pay MannKind Corporation $45 million up front and up to $50 million in milestone payments, plus potential double-digit royalties for a worldwide exclusive licensing and collaboration agreement for development and commercialization of… Read more . . .
-
Johnson & Johnson subsidiary Janssen Pharmaceutical has submitted an NDA for esketamine nasal spray for the treatment of treatment-resistant depression in adults, the company said. Janssen said that it plans to submit an MAA to… Read more . . .
-
Device developer Merxin has announced that a European generics company has acquired exclusive worldwide rights for development of a tiotropium/olodaterol product for the treatment of COPD using Merxin’s MRX004 softmist inhaler. Boehringer Ingelheim markets its… Read more . . .
-
Glenmark Pharmaceuticals said that it has acquired an exclusive license to market a generic tiotropium bromide dry powder inhaler in Western Europe. The DPI, a generic version of Boehringer Ingelheim’s Spiriva Handihaler for the treatment… Read more . . .
-
insys Therapeutics’ epinephrine nasal spray for the treatment of anaphylaxis has received Fast Track designation from the FDA, the company said. In June 2018, Insys said that a Phase 1 study of the nasal spray… Read more . . .
-
Medical Developments International (MVP), which announced in July 2018 that it was expecting a clinical hold letter from the FDA regarding its US clinical program for its Penthrox methoxyflurane inhaler, said that it has now… Read more . . .
-
Device developer Iconovo AB has announced the appointment of Mikael Ekström as its new VP, Development effective September 1, 2018. Ekström held various positions at AstraZeneca over a period of almost 30 years, most recently… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
No events are found.